Supported by an educational grant from Janssen Therapeutics.
Produced by Haymarket Medical Education
The past 3 decades have seen considerable advances in antiretroviral (ART) regimens for HIV-infected individuals. Since many ART agents, combinations, and classes are now available, clinicians who treat HIV have myriad options from which to choose. However, each drug class and each individual agent is associated with its own set of advantages and disadvantages. It is critical that clinicians are knowledgeable about these factors, including the effect of HIV drug selection on patient adherence and the drug resistance and safety profiles of each agent. As new therapies for HIV are continually approved and with a growing number of new options on the horizon, clinicians must be aware of how to best utilize each potential regimen in diverse patient populations.
This educational activity uses a case-based approach to illustrate how HIV treatment should be tailored to the characteristics and needs of each patient. Considerations for selection of an initial ART regimen will be discussed, as will factors to take into account when managing the care of individuals who develop treatment resistance secondary to poor adherence, and considerations for switching virologically suppressed, treatment-experienced patients to a different regimen.
Infectious disease specialists, primary care clinicians, and other health care providers who actively treat patients with HIV/AIDS.
After completing the activity, the participant should be better able to:
Investigate the impact of ART selection on drug resistance, safety, and adherence
Review the updated HHS guidelines for HIV treatment and translate the implications of key changes to actual practice
Implement individualized HIV treatment regimens that meet the needs of diverse patient populations
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, Albert Einstein College of Medicine and Haymarket Medical Education (HME) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
CME Reviewer Victor B. Hatcher, PhD Associate Dean CME Albert Einstein College of Medicine Bronx, NY
Dr. Hatcher has no relevant financial relationships to disclose.
Course Director Barry S. Zingman, MD Medical Director, AIDS Center Clinical Director, Infectious Diseases, Moses Division Professor of Medicine, Albert Einstein College of Medicine Montefiore Medical Center Bronx, NY
Dr. Zingman has no relevant financial relationships to disclose.
Program Faculty Ian Frank, MD Professor of Medicine Director, Clinical Therapeutics Program Penn Center for AIDS Research Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA
Dr. Frank is on the advisory boards of Gilead Sciences and ViiV Healthcare.
W. David Hardy, MD, AAHIVS Senior Director of Evidence-Based Practices Whitman-Walker Health Adjunct Professor of Medicine Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore, MD
Dr. Hardy receives consulting fees from Gilead, GSK/ViiV and preforms contracted research for Amgen, CytoDyn, Gilead, GSK/ViiV, Janssen Therapeutics, and Merck.
Accredited Provider Disclosures
The staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine has nothing to disclose with regard to commercial support.
Publishing Staff Disclosures
Krista Sierra and Susan Basilico of Haymarket Medical Education have nothing to disclose with regard to commercial support.
AMA PRA Category 1 Credit(s)TM
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should only claim those credits commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity will not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Janssen Therapeutics, Albert Einstein College of Medicine, and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. Please proceed until you have successfully completed this activity and completed the post-test and evaluation, and for CME credit only, that you have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.